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The caudal homeobox factor 1 (CDX1) is an essential tran-
scription factor for intestinal differentiation. Its aberrant
expression in intestinal metaplasia of the upper gastroin-
testinal tract is a hallmark within the gastritis-metaplasia-
carcinoma sequence. CDX1 expression is influenced by
certain pathways, such as Wnt, Ras, or NF-B signaling;
however, these pathways alone cannot explain the tran-
sient expression of CDX1 in intestinal metaplasia or the
molecular inactivation mechanism of its loss in cases of
advanced gastric cancer. In this study, we investigated the
epigenetic inactivation of CDX1 by promotermethylation,
as well as the functional link of CDX1 promoter methyl-
ation to the inflammatory NF-B signaling pathway. We
identified methylation-dependent NF-B binding to the
CDX1 promoter and quantified it using competitive elec-
trophoretic mobility shift assays and chromatin immuno-
precipitation. A methylated CDX1 promoter was associ-
ated with closed chromatin structure, reduced NF-B
binding, and transcriptional silencing. Along the gastritis-
metaplasia-carcinoma sequence, we observed a biphasic
pattern of tumornecrosis factor- (TNF-) protein expres-
sion and an inverse biphasic pattern of CDX1 promotermethylation; both are highly consistent with CDX1 pro-
tein expression. The stages of hyper-, hypo-, and hyper-
methylation patterns of the CDX1 promoter were in-
versely correlated with the NF-B signaling activity along
this sequence. In conclusion, these functionally interact-
ing events drive CDX1 expression and contribute to intes-
tinal metaplasia, epithelial dedifferentiation, and carcino-
genesis in the human stomach. (Am J Pathol 2012, 181:
487–498; http://dx.doi.org/10.1016/j.ajpath.2012.04.028)
Gastric carcinogenesis evolves in a stepwise manner1 in
which the development of intestinal metaplasia, within the
gastritis-metaplasia-carcinoma sequence is a pivotal step
that remains poorly understood. Chronic infection with He-
licobacter pylori (H.p.), the main cause of gastric inflamma-
tion, may lead to mucosal atrophy and intestinal metapla-
sia.2 Further accumulation of mutagenic events finally leads
to dysplasia and invasive gastric cancer. This 20-year-old
model initially proposed by Correa has been proven in
several long-term follow-up studies. Transitions from intes-
tinal metaplasias to low-grade dysplasias have been found,
as well as a slight reversibility of intestinal metaplasia, es-
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unpredictable transitions from low- to high-grade lesions,
however, remains, and many attempts were undertaken to
stratify the group of low-grade lesions for reasons of clinical
surveillance.3–7 In this model of gastric carcinogenesis, mi-
lieu factors such as acidic pH or pro-inflammatory cytokines
are able to influence this process.8,9 The underlying cell
signaling cascades, however, are yet to be discovered.
Detailed analyses further distinguish between complete
and incomplete types of intestinal metaplasia or present
oxyntic atrophy of the mucosa as a different kind of meta-
plasia, a so-called spasmolytic polypeptide-expressing
metaplasia, which seems to be a separate mechanism in
the development of gastric cancer.5,10–12
Beyond genetic studies, which revealed, for example,
the background of E-cadherin mutations in gastric can-
cer,13,14 an increasing number of epigenetic studies on
DNA methylation have been performed in gastroenterologi-
cal research in the last years. A PubMed search (using
keywords for gastric cancer and methylation, which was
performed on November 20, 2011) revealed over 800 arti-
cles concerning gastric cancer and methylation. These
studies showed loss of gene expression, particularly of tu-
mor suppressor genes, bearing prognostic values.15,16
Such genes include p16, RUNX3, PCDH10 (Protocadherin
10), and DKK-3, which have biological relevance in the
context of gastric cancer.16–19 Nevertheless, only a minority
of these studies focused on pre-malignant stages in gastric
cancer, such as H.p. gastritis, intestinal metaplasia, and dys-
plasia.20–22
The aberrant expression of evolutionarily conserved
intestinal transcription factors, such as the homeobox cau-
dal-type homeobox factor 1 (CDX1) and caudal-type ho-
meobox factor 2 (CDX2), seem to be crucial for inflamma-
tion-associated intestinal transdifferentiation of stem cells in
the human stomach.23 It has been previously reported that
bile acids activate the CDX2 promoter via NF-B and that
CDX1 seems to play an important role in the development of
Barrett’s esophagus.24 It has yet to be investigated, if epi-
genetic alterations play a functional role in the dysregulation
of these intestine-specific tumor suppressor genes.
With this study, we describe the promoter methylation
level of CDX1 along the gastritis-metaplasia-carcinoma se-
quence. We analyzed DNA-protein interactions and verified
an interactive functional link between CDX1 promoter meth-
ylation and NF-B signaling. These interesting findings for
CDX1 could not be transferred to CDX2, which seems to be
transcriptionally unaffected by promoter methylation.
Materials and Methods
Sequences, CDX1 Promoter Characterization,
CpG Island Detection (European Molecular
Biology Open Software Suite), rVISTA-Analysis
Analyzed sequences refer to GenBank entries: CDX1-mRNA
(NM_001804.2), TNFAIP3-mRNA (NM_006290), CDX2-mRNA
(NM_001265), CDX1 gene and promoter (NC_000005.9),
CDX2 gene and promoter (NC_000013.10), NFKBIA gene
and promoter (NG_007571), organic cation transporter 1(OCT1) gene and promoter (NM_003057.2). Promoter char-
acterization was performed using open source software,
such as rVISTA 2.0 and European Molecular Biology Open
Software Suite (European Molecular Biology Open Software
Suite and rVISTA Anaylsis).25,26
Cell Culture
The human gastric cancer cell lines AGS, 23132/87,
KATO3, and HGT1 were maintained in Dulbecco’s mod-
ified Eagle’s medium or Dulbecco’s minimal essential
medium containing 10% fetal calf serum. As indicated, 24
hours before treatments, cells were plated at optimal
density. Chinese hamster ovary cells were grown in RPMI
1640 medium with 10% fetal calf serum, 1% pyruvate, 1%
penicillin/streptomycin, and 1% glutamine (all from Invit-
rogen, Darmstadt, Germany) at 5% CO2 humidified at-
mosphere.
5-Aza Treatment and TNF- Stimulation
Cell lines were seeded to reach confluence in 96 hours
and treated unstarved. After 24 hours of initial adherence,
cells were cultured for 72 hours with 5-aza-2=-deoxycyt-
idine (5-aza) (Sigma-Aldrich, Taufkirchen, Germany) at
0.5, 1.0, 2.0, 3.0, 4.0, and 5.0 mol/L. Untreated cells
served as controls. Cytotoxicity was measured by cell
counting. For all further experiments, a concentration of 3
mol/L 5-aza was chosen. In addition, AGS cells were
either stimulated 24 hours before harvesting with a solu-
tion of 10 ng/mL of TNF- (R&D Systems, Wiesbaden,
Germany), or were left unstimulated. Cells were lysed in
RLT buffer, and processed for RNA isolation.
RT-PCR
RNA was isolated with the RNeasy Micro Kit (Qiagen,
Hilden, Germany). The primers used for RT-PCR were:
CDX1: forward, 5=-ACAATCCGGCGGAAATCAG-3=, re-
verse, 5=-TTCACTTTGCGCTCCTTTGC-3=; CDX2: for-
ward, 5=-CTGGAGCTGGAGAGGAGTTTC-3=, reverse,
5=-ATTTTAACCTGCCTCTCAGAGAGC-3=; TNFAIP3: for-
ward, 5=-CTGCCCAGGAATGCTACAGATAC-3=, reverse,
5=-ACAAGTGGAACAGCTCGGATTT-3=; GAPDH: for-
ward, 5=-GAAGATGGTGATGGGATTTC-3=, reverse, 5=-
GAAGGTGAAGGTCGGAGTC-3= (Eurofins MWG, Eber-
sberg, Germany). All RT-PCR was performed as
previously described.9 In quantitative PCR experiments,
the targets were compared to glyceraldehydes-3-phos-
phate dehydrogenase. qPCR was performed on a 7500
Fast Real-Time PCR System (Applied Biosystems, Carls-
bad, CA). Results were calculated using the CT-
method.
Electrophoretic Mobility Shift Assay
Nuclear proteins of inflammatory activated, NF-B en-
riched Chinese hamster ovary cells were used in electro-
phoretic mobility shift assay (EMSA), as previously de-
scribed.27 NF-B binding activity was investigated with
IRDye 700-labeled oligos.
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the consensus NF-B binding site of the NFKBIA promoter,
and as a loading control, the promoter of the organic cation
transporter 1 (OCT1), as published previously.28 For the
CDX1 promoter, we generated the following probe: sense
5=-CCCCCGACGGGTTTCCCCCTTTGATTCGCG-3=. This
was obtained in a native unmethylated form and in a
methylated variant with methyl-cytosine bases in sense
and anti-sense oligonucleotides at position X: sense 5=-
CCCCXGAXGGGTTTCCCCCTTTGATTXGXG-3= (Euro-
fins MWG, Ebersberg, Germany). The 20 L reaction
contained 2 L binding buffer (100 mMTris, 500 mMKCl,
10 mmol/L DTT), 1 L of double-stranded poly (dI-dC; 2
g/L), 1 L of 2.5% Tween 20, 1 L of 1% NP-40, 2 g
bovine serum albumin (10 mg/mL), and 0.5 L of 700-
infared labeled-double-stranded NF-B consensus oligo-
nucleotide (50 nmol/L) supplemented with 10 g nuclear
protein in H2O. The mixture was incubated at room tem-
perature for 30 minutes, and then applied on a 4% Lipage
Gel (4°C for 2 hours at 150 V), analyzed, and quantified
by the Odyssey system (Licor; Biosciences GmbH, Bad
Homburg, Germany). For specification, co-incubation ex-
periments with unlabeled consensus and mutant NF-B
oligonucleotides (Santa Cruz Biotechnology, Santa Cruz,
CA) were performed.
EMSA Competition Assay
The CDX1-specific double-stranded oligonucleotide
sense 5=-AGTTGAGGGGACTTTCCCAGG-3= was used in
a non-dye-labeled variant (Eurofins MWG, Ebersberg,
Germany). This unlabeled, unmethylated probe was in-
cubated in descending 10% steps with either the 700-
dye-labeled unmethylated CDX1-specific ds-oligo or the
700-dye-labeled methylated CDX1-specific ds-oligo.
Vice versa, the amount of dye-labeled oligos was raised
in 10% steps. Thus, the affinity of the nuclear extracts to
the dye-labeled and non-dye-labeled probe was semi-
quantitatively calculated by measuring the decrease of
fluorescence intensity in comparison to the total input
probe intensity.
Chromatin Immunoprecipitation-Assay for
Histone Modification and NF-B Binding
Chromatin in confluent AGS cells was cross-linked and
harvested, and the protein-chromatin lysate was frag-
mented to a length between 200 and 1000 bp by soni-
cation. Histone modifications in the CDX1 promoter re-
gion were checked in AGS cells after 5-aza treatment, as
previously described. Chromatin was immunoprecipi-
tated with the following antibodies overnight at 4°C with
rotation: dimethylated histone H3K4 (1:50, H3K4me2;
Cell Signaling, Danvers, MA), dimethylated histone H3K9
(1:25, H3K9me2; Cell Signaling, Danvers, MA). A chro-
matin immunoprecipitation (ChIP) DNA Clean & Concen-
trator kit (ZYMO Research, Orange, CA) was used to
clean and concentrate the chromatin. We designed prim-
ers to amplify the CDX1 promoter area that flanks the
NF-B binding site: forward 5=-CGGCAATTTGTCTC-CTTTTGAACC-3=, reverse 5=-CCCACCCAGGCCTTT-
TATAGCTC-3= (Eurofins MWG, Ebersberg, Germany).
Then AGS cells were treated with 5-aza and TNF-, as
previously described, and were then transferred to NF-B
ChIP experiments using the ChIP-IT Express Kit (Active
Motif, Rixensart, Belgium). The chromatin was incubated
with 3 g/mL p65-NF-B-antibody. The same specific
PCRs flanking the NF-B binding sites were used in this
setting. The NFKBIA promoter served as positive control for
ChIP, as it is a well-known target in NF-B-signaling: for-
ward, 5=-GCAGAGGACGAAGCCAGTTCT-3=, reverse, 5=-
GACTGCTGTGGGCTCTGCA-3= (Eurofins MWG, Ebers-
berg, Germany).
Each ChIP experiment was performed three times.
DNA was eluted in 50 L final volume, and 2 L of each
ChIP-DNA was subjected to qPCR. Fold enrichment in
the binding of histones and in the binding of NF-B to the
CDX1 promoter were determined. The PCRs after ChIP
compared the precipitated genomic fragment covering
the NF-B binding site in the CDX1 promoter to the input
DNAs before precipitation. qPCR was performed on a
7500 Fast Real-time PCR System (Applied Biosystems,
Carlsbad, CA). Results were calculated using the CT-
method.
Tissue Samples
Human formalin-fixed, paraffin-embedded (FFPE) tissue
specimens from the diagnostic files of the Institute of Pa-
thology of the University Hospital Erlangen were analyzed.
For DNA preparation, a collection of 66 gastric mucosa
specimens from 50 patients were investigated (age
range, 24–92; mean, 65; sex distribution M:F, 35:15).
From each sample 1 g DNA was microdissected. The
specimens included 10 cases of normal gastric mucosa,
12 cases of H.p. gastritis, 17 cases of intestinal metapla-
sia, 6 cases of low grade, and 5 cases of high-grade
intraepithelial neoplasias, as well as 16 advanced gastric
adenocarcinomas.
The immunohistochemical study included 121 gastric
mucosa specimens from 51 patients, which underwent
gastric resection (age range, 28–85; mean, 67; sex dis-
tribution m:w, 31:20). The specimens included 33 cases
of normal gastric mucosa, 14 cases of H.p. gastritis, 32
cases of intestinal metaplasia, 12 cases of low-grade,
and 6 cases of high-grade intraepithelial neoplasias, as
well as 24 advanced gastric adenocarcinomas. The
study was stated to be in accordance with local and
national ethical principles as of January 25, 2005.
Bisulfite Sequencing and Pyrosequencing
Bisulfite treatment was performed using the Epitect Bisulfite
Kit (Qiagen, Hilden, Germany). Nonselective methylation
specific PCRs were designed: forward 5=-TTGTGTGAAGT-
TGGTTTAGAATTT-3=, reverse 5=-ACACATAACCCACATA-
CATAATAAC-3= (Eurofins MWG, Ebersberg, Germany).
The amplicon was 505 bp long and covered 49 CG sites.
Amplicons from AGS cells were cloned with the TOPO-TA-
Cloning Kit (Invitrogen, Darmstadt, Germany), 10 clones
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(Qiagen, Hilden, Germany).
A retrograde pyrosequencing assay was designed for
FFPE material. The primer sequences were as follows: for-
ward 5=-GGTAATTTGTTTTTTTTTGAATTTTT-3=, reverse 5=-
CCCCACCCAAACCTTTTATAAC-3= (Eurofins MWG). The
pyrosequencing pipette schemewas designed by Varionostic
(Ulm, Germany) and was as follows: CCRAACCRCCCRC-
RACCCCAACCRAAACRAATTTACATTTCAAAACRAAAA-
AAAACCTCCRAACCRCRAATCAAAAAAAAAAACCCRTC-
RAAAACRAAAAATT.
Immunohistochemistry
Pretreatment of tissue samples was performed as previ-
ously described.9 For CDX1 staining endogenous peroxi-
dase was blocked by 3% H2O2 in Tris buffer for 15 minutes.
The sections were incubated for 30 minutes at room tem-
perature with a goat anti-CDX1 antibody (1:20, Santa Cruz
Biotechnology, Santa Cruz, CA) or overnight with a mouse
anti-TNF- antibody (1:100; Abcam, Cambridge, UK) di-
luted in Antibody Diluent (Dako, Glostrup, Denmark).
CDX1 detection was established on duodenal and co-
lonic mucosa and performed with an horseradish peroxi-
dase-labeled anti-goat Polymer (B-Bridge, Mountain View,
CA). Staining was visualized with diaminobenzidine chro-
mogen (Dako, Glostrup, Denmark). For TNF-, a macro-
phage-rich resorptive inflammation (seroma) served as
positive control. Here, an AP labeled anti-mouse Polymer
(Dako, Glostrup, Denmark) was used with Fast Red visual-
ization afterward. All sections were counterstained with
Mayer’s hemalaun (Merck, Darmstadt, Germany). Negative
controls without primary antibody were run for each sample.
Statistics
Two-way analysis of variance, two-sided t-tests, 2-tests
and Pearson correlations were used. Statistical signifi-
cance was set at P values 0.05.
Results
Demethylation of Highly Methylated CDX1
Promoter Restores CDX1 Expression in Four
Human Gastric Cancer Cell Lines
We treated AGS, HGT-1, 23132/87, and KATO-III cells
with different concentrations of 5-aza-2=-deoxycytidine
(5-aza). A concentration of 3 mol/L 5-aza was used
further on as it showed the lowest cytotoxicity (data not
shown). Bisulfite sequencing covering the whole CpG
island with 49 CG sites in 10 treated versus untreated
clones from the cell culture experiments, which showed
an average decrease in methylation from 95.1% to 62.6%
(2 test, P  0.001) according to data from the litera-
ture.29,30 After 5-aza treatment RT-PCR showed a general
increase in CDX1-mRNA expression in all four cell lines
(data not shown). The higher susceptibility of the demethy-
lated CDX1 promoter is per se an unspecific process attrib-utable to several possibly basic active pathways influencing
CDX1, which we specified exemplarily further on.
In comparison, a basal CDX2-mRNA expression was
generally visible in all four cell lines, even in those known
to have a methylated CDX2 promoter like AGS cells.
5-aza treatment did not consistently increase the amount
of CDX2 PCR product. This is consistent with literature,
suggesting a lack of correlation between CDX2 methyl-
ation status and its transcriptional activity.31
The CDX1 Promoter Contains a Highly
Conserved NF-B Site in a CpG Island
Open source software tools like the EMBOSS and rVista
2.0 were used to further characterize the CDX2 and
CDX1 promoter. For CDX2, EMBOSS confirmed a first
putative CpG island 3800 bp to 3400 bp upstream,
which might be located too far from the coding region to
influence the transcriptional activity. In comparison, EMBOSS
revealed a closer putative CpG island within the CDX1 pro-
moter (Figure 1A) from 400 bp to  100 bp covering 49
CG sites around the transcription start site (Figure 1C). The
previously achieved bisulfite sequencing data verified
highly methylated CGs in the conserved NF-B site (Figure
1B). Previous studies claimed seven putative NF-B sites in
this CpG island.30 However, rVista 2.0 analyses verified only
one highly conserved NF-B site existing in humans, as well
as rodents, at 138 bp (Figure 1C). AGS cells were se-
lected as a model for the following studies.
Stimulation with TNF- Induces a Methylation-
Dependent CDX1-mRNA Expression
We used TNF- as a pro-inflammatory stimulus for acti-
vation of NF-B signaling to investigate the epigenetic
mechanisms of CDX1 inactivation. Experiments were per-
formed three times in triplicates. The two-way analysis of
variance showed that both kinds of treatment were fol-
lowed by a significant increase of the basal CDX1-mRNA
expression in qPCR (P  0.001 for 5-aza and P  0.011
for TNF-). We observed an additive effect on analyzing
the interaction of both treatments (P  0.008).
Therefore, the basal CDX1-mRNA expression in un-
methylated 5-aza-treated AGS cells could be significantly
increased on TNF- treatment (Figure 2A). In contrast, meth-
ylated 5-aza untreated cells were not susceptible to TNF-.
In comparison CDX2-mRNA expression is known to be
slightly decreased after TNF- treatment due to the inter-
action with the PTEN pathway.32 The two-way analysis of
variance confirmed that repression of CDX2-mRNA ex-
pression in qPCR in tendency, but showed no increase of
the basal CDX2-mRNA expression after 5-aza treatment
(P  0.12 for TNF- and P  0.35 for 5-aza) (Figure 2B).
AGS cells are known to have a methylated CDX2 pro-
moter.31 Independent from the methylation status due to
5-aza treatment, the CDX2 expression is restored in the
same way if TNF- is absent. We, conclude, therefore
that the transcriptional reactivity of the CDX2 promoter is
independent from its methylation status, which is consis-
tent with data from the literature.31 To study certain epi-
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cused on CDX1, but not CDX2.
In addition, a methylation-independent induction of the
specific NF-B target gene TNFAIP3 excludes a generally
diminished NF-B transcriptional transactivation in highly
methylated cells. A two-way analysis of variance on
TNFAIP3 showed a significant increase of mRNA expres-
Figure 1. A: The CDX1 promoter analyzed by a CpG-island detection tool
offered by the European Molecular Biology Open Software Suite (EMBOSS). In
the Promoter region starting 1000 bp upstream, the CAG unit represents a
putative CpG island at 600 bp to 1100 bp corresponding to a range from 400
bp to 100 bp in direct relation to the transcription site. B: Bisulfite sequencing of
the highly conserved and validated NF-B site at 138 bp within the CDX1
promoter in native (left) and 5-aza treated AGS cells (right). Note the thymidine
replaced cytosines in the unmethylated state (arrows). C: This CpG-island in
detail shows 49 CGs (black diamonds) also covering an inter species con-
served NF-B binding site at 138 bp. Sequencing primers for cell line analysis
overdrew the whole CpG island, whereas pyrosequencing primers due to the
degraded shorter DNA lengths in FFPE material were designed to be represen-
tative and to detect the NF-B site as the region of interest.sion in qPCR, only on TNF- treatment (P 0.001), but nosignificant interaction on 5-aza treatment (P  0.277).
t-tests for groups of interest of these experiments are
outlined in Figure 2.
Basal restoration of CDX1 after 5-aza treatment is not
attributable to NF-B signaling, but presumably other path-
ways might play a role, as we did not observe a response in
TNFAIP3 gene (Figure 2C). Therefore, NF-B-mediated dif-
ferences in CDX1 expression seemed to be specifically
dependent on the methylation status of the CDX1 promoter.
NF-B Binds to Its CDX1 Promoter Site in a
Methylation-Dependent Manner
We performed EMSAs to determine NF-B binding to the
CDX1 promoter. In establishing NF-B specific EMSAs,
the NFKBIA promoter, a well-known downstream target of
NF-B, served as a positive control. Then we generated a
fluorescence 800-dye-labeled double-stranded oligonu-
cleotide probe from the CDX1 promoter sequence con-
taining the putative NF-B binding site. We confirmed a
sequence-specific DNA-binding activity of the NF-B pro-
tein complex to the CDX1 promoter on incubating it with
nuclear extracts from activated cells enriched with NF-B
protein. Three DNA-protein complexes appeared on the
gel. The ability of NF-B to form heteromeric DNA com-
plexes has been previously published (Figure 3).33–35
The specificity of the EMSA experiment was outlined
by co-incubation of the CDX1 probe with NF-B specific
cold consensus and mutant probes. Incubation with the
consensus probe led to extinction of the specific three
bands, whereas incubation with the mutant probe led to
no change (Figure 3).
Next, we investigated whether methylation alters NF-B
binding to the CDX1 promoter, in vitro, using a modified
CDX1 probe with methylated cytosines. Both complexes
were again observed in EMSA, but with decreased signal
intensity, possibly due to a direct effect of the CDX1 oligo-
nucleotide methylation status (Figure 4, A and C).
We further developed the EMSA to an innovative com-
petitive binding assay, which allows us to quantify the
NF-B binding differences between the methylated and
unmethylated CDX1 probes. To measure different NF-B
affinities, several CDX1 probe mixtures were investigated.
In the first setting, unmethylated labeled and unlabeled
probes weremixed. As expected, the fluorescence intensity
was directly proportional to the mixing ratio. Addition of an
excess of the unlabeled unmethylated probe resulted in
extinction of all three bands, thereby again confirming the
specificity of the EMSA (Figure 4A). In a second setting, the
unmethylated labeled probe was replaced by a methylated
labeled probe. With competition, the visible DNA-protein
complex of the methylated CDX1 probe showed a signifi-
cant faster extinction already at low mixing ratios (Figure
4B). We also quantified the signal intensities (Figure 4D). At
a mixing ratio of 50:50, the ratio of specific signal intensity to
input signal intensity was 46% for the unmethylated probe;
and the ratio was significantly (P  0.001) reduced to 23%
for the methylated probe. Thus, the affinity of NF-B to the
unmethylated CDX1 probe was two-fold higher compared
to the methylated CDX1 probe.
5-aza t
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Promoter for NF-B Binding
We used ChIP to validate the results of the EMSA exper-
iments in vital cells. Demethylation by 5-aza treatment is
known to switch between repressive and permissive
chromatin status. Particular histone modifications lead to
Figure 2. TNF- significantly promotes CDX1-mRNA levels in unmethylated
untreated AGS cells and not inducible by TNF-. B: CDX2 mRNA is lowered
induces TNFAIP3 mRNA expression, independent of the methylation-status in
¶P  0.92; P  0.002.
Figure 3. Electrophoretic mobility shift assay with DNA probes for the CDX1
promoter containing the putative NF-B binding site and OCT1 probe as
loading control. Each probe was added alone (Ø) or incubated with NF-B
enriched nuclear extracts (X). The specificity of the three bands showing
NF-B bindings (arrows) was confirmed by co-incubation either with a cold
NF-B consensus probe ( cons) or with a cold NF-B mutant probe
(mut).altered folding of the nucleosomal fiber that renders chro-
mosomal domains more accessible.36 Histone methyl-
ation patterns should indicate chromatin activity status at
the CDX1 promoter after 5-aza treatment. We used an
antibody against dimethylated histone H3 lysine 4
(H3Me2Lys4) and against dimethylated histone H3 lysine
9 (H3Me2Lys9) to confirm an open or closed chromatin,
respectively.37 Genomic qPCRs experiments were per-
formed measuring the differences between Ct values of
precipitated DNA versus input DNA. Indeed, the ratio of
precipitated CDX1 promoter-to-input chromatin increased
from 0.62 to 1.26 after 5-aza treatment for H3me2Lys4 IP,
whereas the ratio of precipitated CDX1 promoter-to-input
chromatin decreased from 1.62 to 0.80 for H3me2Lys9 IP.
These experiments confirm permissive chromatin formation
along the CDX1 promoter by 5-aza treatment.
5-Aza Treatment Induces CDX1 Up-Regulation
by Increased NF-B Binding to the CDX1
Promoter
To determine in vivowhether CDX1 up-regulation is due to
direct transcriptional activation by NF-B promoter bind-
ing, we used the p65-NF-B antibody to immunoprecipi-
tate the chromatin from AGS cells with or without 5-aza
treatment and with or without TNF- stimulation (Figure 5,
A and B). The experiment was performed three times and
measured in triplicates.
The two-way analysis of variance showed that both treat-
ments were followed by a significant enrichment (P 
0.001) of the genomic fragment containing the NF-B bind-
ing site. We observed an additive effect on analyzing the
interaction of both treatments (demethylation and en-
hanced inflammation) (P  0.004) (Figure 5, A–C).
We observed a maximal difference of 9.8-fold increase in
NF-B binding to the CDX1 promoter between unmethy-
lated/TNF--treated versus methylated/TNF-untreated
AGS cells. This factor can be split into two categories. A
5.5-fold increase is attributable to the demethylated status
reated AGS cells. A: CDX1 mRNA expression is blocked in methylated 5-aza
TNF treatment independent of its methylation status. C: TNF- (as control)
reated and untreated AGS cells. *P  0.026; †P  0.001; ‡P  0.12; §P  0.86;5-aza t
duringdue to 5-aza treatment alone, whereas a factor of 1.8 is due
CDX1 Methylation and NF-B in Gastric Cancer 493
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status, there was no significant difference between TNF-
treated or untreated AGS cells (P  0.41) (Figure 5C).
These ChIP experiments confirmed experimentally the
methylation-dependent genomic binding of NF-B to the
CDX1 promoter at the proposed position. Furthermore these
epigenetically modified protein-DNA-interactions are highly
consistent with the previously shown mRNA-expression ex-
periments (Figure 1).
A Biphasic Pattern of CDX1 Promoter-Methylation Is
Observed in Human Tissues Along the Gastritis-
Metaplasia-Carcinoma Sequence
We analyzed the CDX1 promoter methylation status in
human FFPE samples by pyrosequencing along the gas-
tritis-metaplasia-carcinoma sequence. Due to DNA frag-
mentation in FFPE material, the assay had to be short-
ened and covers 13 CG sites within the CpG island,
including the conserved NF-B site of the CDX1 pro-
moter. The bisulfite sequencing data in this area regarding
the 10 treated versus untreated clones from the cell culture
experiments were chosen to judge the representativeness
of this shortened assay. Here a decrease in methylation
from 92.3% to 68.0% (2-test, P  0.001) within the ana-
lyzed amplicon was found and thus indicated values that
match in comparison to the methylation status of the whole
CDX1 promoter as previously described.No statistic correlations to sex or age were detectable.
Indeed, the highest degree of methylation was ob-
served in normal gastric mucosa, whereas the lowest
degree was noticed in specimens with low-grade intra-
epithelial neoplasia. The level of hypermethylation in-
creases again in gastric cancer (Figure 6). Here,
higher degrees of methylation at the CDX1 promoter
were associated with loss of differentiation and higher
tumor grade.
In a subgroup of nine patients, material was available
from carcinomas and corresponding intestinal metapla-
sias. In these cases, a significant lower methylation level in
intestinal metaplasia (22,6%) than in gastric cancer (30,4%)
was detectable (paired t-test, P  0.02), which indicated
specific methylation patterns in certain lesions along the
gastritis-metaplasia-carcinoma-sequence rather than gen-
eral methylation effects of the whole mucosa.
The Biphasic CDX1 Protein Expression Along
the Gastritis-Metaplasia-Carcinoma Sequence
Reflects the Inflammatory Activity and the CDX1
Promoter-Methylation Pattern
We performed TNF- and CDX1 immunohistochemical
staining to correlate the observed epigenetic alterations
with the protein expression in human tissues. The ob-
served expression levels of normal, gastritis metaplasia,
Figure 4. A: Competitive EMSA of a labeled unmethylated
probe with an unlabeled unmethylated probe of the CDX1
promoter mixed in decreasing ratios of 10% steps. B: Quan-
titative analysis of the signal intensity of the unmethylated
probe compared to the total inserted probe. The affinity of
NF-B to both probes was the same reaching half values at
the 50:50 mixing ratio. C: Competitive EMSA of a labeled
methylated probe with an unlabeled unmethylated probe of
the CDX1 promoter in a descending mixing ratio in 10%
steps. Note the fast extinction of the NF-B binding site
(arrows) of the methylated probe due to the lesser affinity of
the protein compared to the unlabeled unmethylated probe.
D: Quantitative analysis of the signal intensity of the meth-
ylated probe in comparison to the total inserted probe. The
expected bisection of the intensity is not reached at the 50:50
mixing ratio but at a ratio of 70:30, indicating a twofold
stronger binding of NF-B to the unmethylated probe.dysplasia, and carcinoma samples are shown in Figure 7.
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normal gastric tissue, reaching highest levels in intestinal
metaplasia and decreased again in carcinoma (Figure
8A). No statistic correlations to sex or age were detect-
able. As previously reported,23 normal gastric mucosa
did not show any CDX1 protein expression. The strongest
nuclear staining of the CDX1 protein was observed in
intestinal metaplasia, as well as in low-grade dysplasia.
In gastric carcinoma, the CDX1 expression was remark-
ably decreased. The inflammatory activity measured by
TNF- expression showed a highly significant direct cor-
relation to CDX1 expression at Pearson’s value of 0.419
(P  0.001).
In addition, the two groups for pyrosequencing and
immunohistochemistry shared samples from the same
patients in n  25 cases, mainly in the category of meta-
plasia and carcinoma. These overlapping cases showed
a significantly negative correlation between the methyl-
ation level and protein expression at Pearson value
0.427 (P 0.033). At a cut-off level of 26% for the CDX1
promoter methylation, a significant (P  0.03) decrease
in CDX1 protein expression could be observed (Figure
8B). The protein expression profile of CDX1 seems to
follow the CDX1 epigenetic profile along the gastritis-
Figure 5. A: ChIP assay using an NF-B-p65 antibody and PCR directed to
the CDX1promoter. B: The same PCR assay in the native nuclear chromatin
before precipitation is shown (input control). C: The fold-change of the
precipitated genomic fragment containing the NF-kB binding site of the
CDX1 promoter was determined via quantitative qPCR, showing a significant
10-fold stronger protein-DNA interaction of NF-B with the CDX1 promoter
in the unmethylated TNF- stimulated cells as an additive effect. *P  0.018;
†P  0.001.metaplasia-carcinoma sequence.Discussion
CDX1 and CDX2 are intestine-specific transcription fac-
tors of the caudal homeobox transcription factor family
and essential for embryonal gut development.23 In close
interaction, CDX2 transcriptionally activates CDX1 by di-
rect promoter binding.38 Inversely, Cdx1 overexpression
in transgenic mice reduces Cdx2 expression on mRNA
and protein levels.39 Functionally, CDX1 and CDX2 are
able to substitute each other in the maintenance of the
crypt-villus-axis and are frequently co-expressed.40 We,
as well as others, found that CDX1 and CDX2 are indis-
tinguishably present in different types of intestinal meta-
plasia.41 In our study, therefore, complete and incom-
plete types of intestinal metaplasia were grouped
together. But also differences between CDX1 and CDX2
exist. So Cdx2 transgenic mice showed intestinal meta-
plasia, as well as oxyntic atrophy of the gastric mucosa,
whereas in Cdx1 transgenic mice intestinal metaplasia
was seen alone.42 Inflammatory signals like TNF- can
promote CDX1 expression, but diminish CDX2 expres-
sion through the PTEN pathway.32 Whereas the respon-
siveness of the CDX1 promoter is dependent from its
methylation state, this does not account for CDX2. In our
study, CDX2 maintained a basal transcriptional activity
and responsiveness of its promoter independent from its
methylation state, which is consistent with literature.31 To
study functionally epigenetic events in gastric carcino-
genesis, we therefore focused on CDX1.
The loss of CDX1 causes dedifferentiation of gastrointes-
tinal cancers associated with a higher tumor grade,43 and
Figure 6. Semi-quantitative depiction of the methylation pattern along the
inflammation-metaplasia-carcinoma sequence including the NF-B binding
site of the CDX1 promoter. High degrees of methylation were detectable in
the normal human gastric mucosa. The initial hypo-methylation in Helico-
bacter gastritis and intestinal metaplasia reaches the lowest levels in low-
grade dysplasia. Hyper-methylation gains importance in high-grade dysplasia
and gastric carcinoma. Pyrosequencing data that was not interpretable due to
background signals or shortened fragments were omitted (missing circles).
IEN, intraepithelial neoplasia.
(D). Epi
cer (H).
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tumor suppressive role an oncogenic role has been found
for CDX1 as well. CDX1 can promote intestinal cell prolifer-
ation mediated through the induction of PAP I up-regulation
Figure 7. CDX1- and TNF- immunohistochemical staining in normal (A
respectively. Note the strong CDX1 nuclear staining in intestinal metaplasia
B, left side). Loss of nuclear staining is observed in invasive gastric cancer
dysplasia (F, G). Reduced levels of TNF- are found in invasive gastric can
Figure 8. A: Immunohistochemical protein expression of nuclear CDX1 and
cytoplasmatic TNF- along the gastritis-metaplasia-carcinoma sequence from
the left to the right: 33 cases of normal gastric mucosa (Nor), 14 cases of
Helicobacter pylori (H.p.) gastritis (H.p.), 32 cases of intestinal metaplasia
(i.M.), 12 cases of low-grade (Lg) intraepithelial neoplasia, 6 cases of high
grade (Hg) intraepithelial neoplasia, and 24 gastric adenocarcinomas (CA).
Note the parallel dome shape of increase and decrease of both proteins along
the sequence. B: At a cut-off of 26%, the CDX1 promoter methylation clearly
distinguishes between samples with high and low CDX1 protein expression
levels, independent of the point along the gastritis-metaplasia-carcinoma
sequence (data taken from an overlap of n  25 samples, in which the
molecular and immunohistochemical data were available). Error bars depict
a confidence interval of 95%. *P  0.001; †P  0.01; ‡P  0.03.of the proliferating cell nuclear antigen and down-regula-
tion of the cdk inhibitor p21WAF.31–32,44–46 CDX1, further-
more, is a target of oncogenic pathways of early colon
cancerogenesis, such as the APC/-catenin and the Ras
pathways.47–49 However, these effects did not alter
chemically induced colon carcinogenesis in Cdx1 knock-
out or Cdx1-villin transgenic mice.39,40 These data ques-
tion the role of CDX1 as an oncogene.
A tumor suppressor function of CDX1 is seen, as it can
counteract proliferation in colon cancer cell lines by re-
ducing cyclin D1 gene expression through altered Rb-
pathway signaling.50 Noteworthy, CDX1 can induce a
panel of intestinal differentiation genes, such as Muc2,
CK20, aminopeptidase N, villin, and peroxisome prolif-
erator-activated receptor-.44,51–53 In addition, CDX1 in-
creases E-cadherin-mediated cell adhesion.54
In summary, CDX1 plays a key role in regulating intes-
tinal epithelial differentiation, permeation of cell adhesion,
and control of proliferation.39
Focusing on the upper gastrointestinal tract, CDX1 is
aberrantly expressed in intestinal metaplasias of the stom-
ach, as well as the gastroesophageal junction,23,30,55 which
is consistent with our immunohistochemical findings. Intes-
tinal metaplasia in the stomach is induced by chronic in-
flammation caused by Helicobacter pylori or by reflux dis-
ease in Barrett’s mucosa, respectively. Bile salts and
inflammatory signals caused by Helicobacter pylori pro-
mote this metaplastic CDX1 and CDX2 expression.8,30 In
stritis-metaplasia (B, F), dysplasia (C, G) and carcinoma (D, H) samples,
side) and dysplasia (C) in contrast to normal gastric or gastritis mucosa (A,
thelial cytoplasmatic TNF- staining is enhanced in gastritis-metaplasia and
Magnification 100., E), ga
(B, righttransgenic mouse models, Cdx1 and Cdx2 indepen-
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Hence, the metaplastic expression of both caudal ho-
meobox genes is strongly linked to inflammatory stimuli.
A relevant regulatory mechanism mainly attributed to
CDX1 expression is methylation. In colon cancer cell
lines, CDX1 gene expression is down-regulated by meth-
ylation and restorable via 5-aza treatment.29,56,57 Dem-
ethylation alone, for instance, through deprivation of folat
donors, however, does not successfully restore CDX1
expression.58 Beyond these descriptive data, only a few
studies combine the promoter methylation status of CDX1
with functional cell signaling cascades. In colon cancer
cell lines, CDX1-mRNA levels increased dose-response-
related after inducing nuclear NF-B-p65 signaling.29 In
Barrett’s mucosa bile salts and acid provoke an inflam-
matory response. Here, methylation of the CDX1 pro-
moter was correlated with an altered susceptibility to
NF-B signaling.30 Methylation of the CDX1 promoter
further influences the synergistic interaction of Cdx2 on
the Cdx1 promoter in gastric mouse models.38
We investigated the level and significance by which
NF-B signaling on the CDX1 promoter is impaired by its
methylation. We showed that the CDX1 promoter is highly
methylated in gastric cancer cell lines and CDX1 expres-
sion is restorable after 5-aza treatment, which may be
attributable to a basal activity of other already mentioned
CDX1 inducing pathways. We observed a significant in-
crease of CDX1 expression after an inflammatory stimu-
lus in case of an unmethylated promoter. EMSAs con-
firmed experimentally the existence of a highly conserved
NF-B binding site within a CpG island of the CDX1
promoter. Competitive EMSAs were designed as a new
quantitative tool for the investigation of methylation-modified
protein-DNA interactions. In detail, methylation of the NF-B
binding site significantly impaired direct NF-B-p65 binding
by two-fold. In ChIP experiments the binding ability of NF-
B-p65 to the methylated CDX1 promoter was even stron-
ger reduced (ie, up to 10-fold). Here the shownmethylation-
dependent heterochromatin formation enhances the
methylation-specific transcriptional silencing.36,37
In summary, NF-B signaling is able to transcriptionally
activate CDX1 expression by direct binding on its implic-
itly unmethylated promoter. In normal gastric mucosa,
CDX1 is not expressed due to high levels of CDX1 pro-
moter methylation and absence of inflammation. As
shown here, the methylation level of the CDX1 promoter
decreases during Helicobacter pylori gastritis and intesti-
nal metaplasia, and reaches the lowest level in low-grade
intraepithelial neoplasia of the stomach. This effect is
attributable to the phenomenon of global hypomethyla-
tion, as seen in the early stages of cancer.59 Indeed, a
decrease to a methylation level of 26% still allows detect-
able CDX1 protein expression. This threshold is reached
between gastritis and intestinal metaplasia. It could be
presumed that there several additional factors that might
influence the transdifferentiation process, such as the
endurance of the inflammatory process, other signaling
cascades, or the intensity of inflammation. For example,
TNF- expression, which is known to mediate NF-B sig-
naling in Helicobacter pylori infection,60 might contribute
to this phenomenon, as we noticed an inversely dome-shaped expression profile along the gastritis-metaplasia-
carcinoma sequence (Figure 8A) in comparison to the
CDX1 methylation pattern. We suggest that in intestinal
metaplasia the synergistic effect of low methylation and
increased inflammation now activates the CDX1 promoter
and initiates intestinal transdifferentiation. During further
tumor progression in gastric carcinogenesis, the level
of CDX1 promoter methylation raises again, whereas
TNF- expression decreases. Therefore, the inflamma-
tory NF-B signaling again loses its impact on the CDX1
promoter and CDX1 expression diminishes. This loss of
an intestine-specific transcription factor has already been
described for colorectal cancer,29 indicating dedifferen-
tiation of carcinoma, and could therefore be transferred
to gastric cancer. In our study, CDX1 methylation was
significantly lower in metaplasia than in associated car-
cinoma. In our opinion, this is a strong argument for lesion
associated methylation patterns rather than generally al-
tered methylation levels of the whole organism, which is
discussed as highly controversely.31,61 Long-term fol-
low-up studies showed that the progression from low-
grade lesions to high-grade lesions still could not be
predicted, which is what leads to problems in healthcare
and surveillance recommendations.3,5,62 Here, the rais-
ing CDX1 methylation pattern from low- to high-grade
lesions might serve as a suitable predictive biomarker.
In conclusion, the methylation dependent NF-B bind-
ing on the CDX1 promoter points out that epigenetic
DNA-modification fits into the context of cell signaling
cascades. This helps to explain certain events in carcino-
genesis, as in our case, inflammation-associated intestinal
metaplasia. For the first time, we described a biphasic
CDX1 promoter methylation pattern along the gastritis-
metaplasia-carcinoma sequence, in which stages with hy-
permethylation are interrupted with intervals of hypomethy-
lation. Further studies on DNA-methylation should
therefore be kept in mind for the possible co-existence of
hyper- and hypo-methylation events, and rely on func-
tional regulatory aspects between descriptive methyl-
ation data and cell signaling.
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